Sangamo Therapeutics’ (SGMO) “Buy” Rating Reiterated at HC Wainwright

Sangamo Therapeutics (NASDAQ:SGMOGet Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a report issued on Monday, Benzinga reports. They presently have a $3.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside of 284.47% from the stock’s previous close.

A number of other research firms have also recently commented on SGMO. StockNews.com began coverage on shares of Sangamo Therapeutics in a research report on Friday, February 2nd. They set a “sell” rating for the company. Truist Financial reissued a “hold” rating on shares of Sangamo Therapeutics in a report on Tuesday, November 7th. Wells Fargo & Company reissued an “equal weight” rating and set a $1.00 target price on shares of Sangamo Therapeutics in a report on Monday, November 6th. Finally, Royal Bank of Canada reissued a “sector perform” rating and set a $2.00 target price (down previously from $6.00) on shares of Sangamo Therapeutics in a report on Friday, November 3rd. Two research analysts have rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $4.68.

Get Our Latest Stock Report on Sangamo Therapeutics

Sangamo Therapeutics Price Performance

SGMO stock traded up $0.21 during midday trading on Monday, reaching $0.78. 4,617,299 shares of the company were exchanged, compared to its average volume of 1,556,037. The business has a 50-day moving average price of $0.48 and a two-hundred day moving average price of $0.63. Sangamo Therapeutics has a one year low of $0.29 and a one year high of $3.32. The firm has a market capitalization of $138.39 million, a price-to-earnings ratio of -0.54 and a beta of 1.04.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of SGMO. Wasatch Advisors LP grew its holdings in shares of Sangamo Therapeutics by 25.0% during the second quarter. Wasatch Advisors LP now owns 17,052,440 shares of the biopharmaceutical company’s stock worth $22,168,000 after purchasing an additional 3,410,023 shares during the last quarter. Acadian Asset Management LLC increased its holdings in Sangamo Therapeutics by 502.7% in the 2nd quarter. Acadian Asset Management LLC now owns 2,821,980 shares of the biopharmaceutical company’s stock worth $3,665,000 after acquiring an additional 2,353,741 shares during the last quarter. BlackRock Inc. grew its holdings in Sangamo Therapeutics by 15.4% during the 3rd quarter. BlackRock Inc. now owns 14,264,458 shares of the biopharmaceutical company’s stock valued at $69,894,000 after buying an additional 1,898,292 shares in the last quarter. State Street Corp lifted its position in Sangamo Therapeutics by 25.3% in the 1st quarter. State Street Corp now owns 7,775,327 shares of the biopharmaceutical company’s stock worth $45,175,000 after buying an additional 1,570,740 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in Sangamo Therapeutics by 10.5% in the third quarter. Vanguard Group Inc. now owns 12,731,109 shares of the biopharmaceutical company’s stock valued at $62,383,000 after purchasing an additional 1,205,951 shares during the last quarter. Institutional investors and hedge funds own 59.81% of the company’s stock.

About Sangamo Therapeutics

(Get Free Report)

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.

Further Reading

Analyst Recommendations for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.